With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...

The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word ...

The stock price of BridgeBio plunged 15% Thursday as Pfizer’s reported decision to withdraw a tafamidis patent in the European Union triggered fears of earlier generic entry in the blockbuster ...

The leaders of this year’s list of the most anticipated drug launches will likely come as no surprise: Fierce’s annual r | On this week’s "The Top Line," Fierce’s Andrea Park and Gabrielle Masson dive ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Merz Therapeutics has launched a punchy marketing campaign for Parkinson’s disease drug Inbrija, working Muhammad Ali quotes ...

On the branded side of things, Sun’s skin cancer offerings include Odomzo for basal cell carcinoma and Unloxcyt, an ...

The Consolidated Appropriations Act of 2026, signed by Trump on Feb. 3, includes a provision reinstating the Mikaela Naylon ...

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...